Q4 2024 Earnings Call Transcript March 25, 2025 X4 Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0 ...

XFOR READ THE FULL XFOR RESEARCH REPORT Business Update Full Enrollment of Phase 3 4WARD Trial Expected in 2H25 X4 ...

In the assessment of 12-month price targets, analysts unveil insights for X4 Pharmaceuticals, presenting an average target of ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on X4 Pharmaceuticals (XFOR – Research Report) and ...

X4 Pharmaceuticals Inc (XFOR) navigates a challenging landscape with strategic cost reductions and promising product ...

June S&P 500 E-Mini futures (ESM25) are down -0.11%, and June Nasdaq 100 E-Mini futures (NQM25) are down -0.19% this morning, pointing to a slightly lower open on Wall Street after yesterday’s rally, ...

Reports Q4 revenue $1.4M vs. $0 last year. “As expected, 2024 was a transformative year for the company and our momentum has continued into ...

X4 Pharmaceuticals highlights 2024 as transformative with XOLREMDI's U.S. launch, international expansion, & Phase 3 trial progress.

Today, several major companies are expected to report earnings: Canadian Solar (CSIQ), Cormedix (CRMD), GameStop (GME), ...

BOSTON (AP) — BOSTON (AP) — X4 Pharmaceuticals, Inc. (XFOR) on Tuesday reported a loss of $39.8 million in its fourth quarter. On a per-share basis, the Boston-based company said it had a loss of 20 ...

Maravai LifeSciences Holdings Inc (MRVI) is expected to report $-0.07 for 4Q. McCormick & Co Inc (MKC) is expected to report $0.64 for 1Q. Movado Group Inc (MOV) is expected to report $0.39 for 4Q.

X4 Pharmaceuticals (NASDAQ:XFOR) is scheduled to announce Q4 earnings results on Tuesday, March 25th, before market open. The consensus EPS Estimate is -$0.16 (-60.0% Y/Y) and the consensus Revenue ...